Skip to main content
. Author manuscript; available in PMC: 2021 Jan 21.
Published in final edited form as: Sci Transl Med. 2020 Jun 24;12(549):eaay6570. doi: 10.1126/scitranslmed.aay6570

Fig. 2. Scaled estimates and meta-analysis of BMD-increasing SOST variants with risk of osteoporosis and fracture.

Fig. 2

Estimates are scaled to match the effect of romosozumab (210 mg monthly for 12 months) on LS-BMD (0.09 g/cm2; see Materials and Methods) and aligned to the BMD-increasing alleles. A total of 15,239 cases of osteoporosis and 53,074 cases of fracture were analyzed. See Materials and Methods for outcome definitions. Boxes represent point estimates of effects. Lines represent 95% CIs.